Charles Schwab Investment Management Inc Next Cure, Inc. Transaction History

Charles Schwab Investment Management Inc

$519 Billion
Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Next Cure, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 10,000 shares of NXTC stock, worth $13,100. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,000

Previous 10,000 -0.0%

Holding current value

$13,100

Previous $22,000 31.82%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	BUY	$5.7 - $9.1 $57,000 - $91,000	10,000 New	10,000 $60,000
Q3 2021 Nov 16, 2021	SELL	$6.74 - $8.02 $410,263 - $488,177	-60,870 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$7.6 - $10.28 $282,856 - $382,601	-37,218 Reduced 37.94%	60,870 $489,000
Q1 2021 May 17, 2021	BUY	$9.81 - $13.88 $21,591 - $30,549	2,201 Added 2.3%	98,088 $982,000
Q4 2020 Feb 16, 2021	BUY	$9.47 - $12.43 $68,591 - $90,030	7,243 Added 8.17%	95,887 $1.05 Million
Q3 2020 Nov 13, 2020	BUY	$8.15 - $21.17 $89,796 - $233,251	11,018 Added 14.19%	88,644 $781,000
Q2 2020 Aug 14, 2020	BUY	$21.19 - $40.2 $176,618 - $335,067	8,335 Added 12.03%	77,626 $1.67 Million
Q1 2020 May 15, 2020	BUY	$32.32 - $58.37 $51,259 - $92,574	1,586 Added 2.34%	69,291 $2.57 Million
Q4 2019 Feb 07, 2020	BUY	$25.0 - $92.22 $996,750 - $3.68 Million	39,870 Added 143.24%	67,705 $3.81 Million
Q3 2019 Nov 08, 2019	BUY	$15.73 - $41.6 $32,859 - $86,902	2,089 Added 8.11%	27,835 $859,000
Q2 2019 Aug 09, 2019	BUY	$14.16 - $20.64 $364,563 - $531,397	25,746 New	25,746 $386,000

Others Institutions Holding NXTC

# of Institutions

Shares Held

16M

Call Options Held

1.4K

Put Options Held

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Next Cure, Inc. Transaction History